在患有晚期子宫内膜癌的患者中,Lenvatinib瘤成和戒断反弹反应
Clarissa Lam1, Debra Sarasohn2, Britta Weigelt3
1Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
在接受伦瓦提尼布加 pembrolizumab 治疗的子宫内膜癌患者中,停止服用伦瓦提尼布 (一种氨酸激酶抑制剂) 可能会导致疾病迅速复发. 重新开始使用伦瓦提尼布可能会导致重复反应,这表明进一步研究戒断效应.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 伦瓦提尼布是一种多位氨酸激酶抑制剂 (TKI),与pembrolizumab (PD-1 抑制剂) 结合,已被批准用于晚期子宫内膜癌.
- 这种组合疗法已显示出有效性,但暂停治疗的效果尚未完全理解.
研究的目的:
- 描述在患有晚期子宫内膜腺癌的患者中停止使用伦瓦替尼布后疾病复发的现象.
- 为了研究在戒断诱导的疾病爆发后重新开始使用伦瓦替尼布时可能出现重复反应的可能性.
主要方法:
- 对三名患有晚期子宫内膜腺癌的患者的病例系列分析,这些患者接受了伦瓦提尼布加布罗利祖马布治疗.
- 在停止服用伦巴替尼布后观察疾病进展,并在重新开始服用伦巴替尼布后观察反应.
主要成果:
- 三名患者经历了稳定或缓慢的进展在lenvatinib加上 pembrolizumab.
- 在停止服用伦瓦替尼布后,所有患者都表现出快速的症状性疾病增长 (戒断反弹).
- 在这些患者中,重新启动伦瓦提尼布导致重复的疾病反应和症状缓解.
结论:
- 伦瓦提尼布的戒断反弹是晚期子宫内膜癌患者的一个显著现象,可能是由上调的瘤信号驱动的.
- 停药后对伦瓦提尼布的重复反应表明药物和瘤生物学之间的复杂相互作用.
- 需要进一步的研究来阐明伦瓦提尼布戒断反弹的机制,并探索减轻疾病爆发的策略.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Treatment Resistant Cancers
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
